Opinion|Videos|January 10, 2025
Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What, in your opinion, is the definition of the transplant-ineligible population for multiple myeloma?
- With the growing use of MRD as a biomarker, what challenges remain in standardizing its use across different treatment settings and trials?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq
2
Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs
3
Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries
4
ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries
5
